As the demand for accessible and scalable cancer screening solutions continues to grow, Vitae Biomedical Co., Ltd. is advancing a urine-based, non-invasive detection platform aimed at transforming early cancer screening.

The company’s lead product, a urine-based lung cancer detection reagent, has obtained CE IVD certification and is capable of detecting multiple lung cancer subtypes. When used in combination with low-dose computed tomography (LDCT), the test demonstrates up to 99% sensitivity and 95% specificity, significantly enhancing diagnostic accuracy and efficiency in clinical settings.

Even as a standalone tool, the test achieves approximately 85% accuracy, making it suitable for initial screening in general populations, ongoing monitoring of high-risk groups, and deployment in regions with limited access to advanced medical infrastructure.

Vitae Biomedical continues to optimize its platform through integration with real-time detection technologies, with the goal of enabling faster and more precise multi-disease testing in the future.

Expanding Global Reach Through IP and Clinical Collaboration

The company has established a strong intellectual property foundation, with core patents granted in the United States, Japan, Australia, and Taiwan, and additional filings underway across Europe and Asia.

On the clinical front, collaborations with leading medical centers in Taiwan are supporting validation and real-world application. At the same time, Vitae Biomedical is actively engaging with partners in emerging markets such as Singapore, Malaysia, and Thailand to accelerate regulatory approvals and commercialization efforts.

Strengthening Industry Engagement and Partnership Opportunities

Through participation in international forums and industry events, the company seeks to establish meaningful collaborations with partners who share a focus on non-invasive diagnostics and early disease detection.

Vitae Biomedical welcomes partnerships across strategic investment, co-development, and market deployment, aiming to accelerate the global adoption of urine-based lung cancer screening and contribute to more accessible healthcare solutions.